BARDA biothreat contract could bring $40M to Tetraphase

BARDA biothreat contract could bring $40M to Tetraphase

January 25, 2012

Synthetic chemistry company Tetraphase Pharmaceuticals Inc. of Watertown could get $40 million from a federal contract to develop an antibiotic to potentially treat illnesses resulting from biological threats such as anthrax, tularemia or pestis, the company told Mass High Tech in an interview.

Click on Mass High Tech logo to view full article